Javier Escaned et al. JCIN 2018;11:

Slides:

Advertisements

Similar presentations

Trial profile Fox K et al. Lancet 2008;372:

Advertisements

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Clinical Outcomes with Newer Antihyperglycemic Agents

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.

4S: Scandinavian Simvastatin Survival Study

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction †

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Value of Platelet Reactivity in Predicting Response.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Discontinuation of medication after nonfatal event: MI

The SPRINT Research Group

Figure 1 Ischaemic endpoints

LEADER trial: Primary Outcome

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

ADenosine Vasodilator Independent Stenosis Evaluation II

Clinical need for determination of vulnerable plaques

Long-term clinical outcome of elderly patients with acute coronary syndrome treated with early percutaneous coronary intervention: Insights from the BASE.

Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction by Suzanne V. Arnold,

Circ Cardiovasc Interv

Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Bjarne L. Nørgaard et al. JACC 2018;72:

Nat. Rev. Cardiol. doi: /nrcardio

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

(p < for noninferiority)

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

Hexabrix Key Clinical Review Le Feuvre, 2006

Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT Coronary microvascular.

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

(p = for noninferiority)

Potential mechanisms whereby statins may reduce the risk of stroke

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different.

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

Flow Diagram of the Trial Selection Process

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Baseline Characteristics of the Patients – Part I

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Adjusted relative risk Adjusted odds ratio

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Davide Capodanno et al. JCIN 2009;2:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Increased Rehospitalization Rate After Coronary Bypass Operation for Acute Coronary Syndrome: A Prospective Study in 200 Patients Staffan Bjessmo, MD,

Tanveer Rab et al. JCIN 2017;10:

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Study flow chart and diagnosis at discharge from ED

Performance of the Manchester Acute Coronary Syndromes decision rule in the derivation study. Performance of the Manchester Acute Coronary Syndromes decision.

Presentation transcript:

Javier Escaned et al. JCIN 2018;11:1437-1449 Cumulative Risk for Primary Endpoint (Major Adverse Cardiac Events) by Clinical Presentation in Patients Assessed With Fractional Flow Reserve and Instantaneous Wave-Free Ratio in the Deferred Population Shown is the cumulative risk for the composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization at 1 year, stratified according to clinical presentation with either stable angina pectoris (SAP) or acute coronary syndrome (ACS). Data for fractional flow reserve (FFR) (left) and instantaneous wave-free ratio (iFR) (right) are displayed. Javier Escaned et al. JCIN 2018;11:1437-1449 2018 The Authors